For research use only. Not for therapeutic Use.
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer[1][2].
Ociperlimab (BGB-A1217; 0-10 μg/mL) enhances IFN-γ secretion by cytomegalovirus-specific T cells[1].
Ociperlimab (1-1000 ng/mL) activates NK and monocytes in an Fc-dependent manner[1].
Ociperlimab removes TIGIT from T cell surface through Fc-dependent endocytosis in vitro[1].
Ociperlimab (BGB-A1217; 3 and 10 mg/kg; i.p.; CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice) elicits anti-tumor efficacy in an Fc-dependent manner[1].
| Catalog Number | I041564 |
| CAS Number | 2342597-93-5 |
| Purity | ≥95% |
| Reference | [1]. Chen X, et, al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. Front Immunol. 2022 Feb 22;13:828319. [2]. Zhu J, et, al. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation. Mol Biol Rep. 2022 Dec 26. |
